Modus Therapeutics Holding Ab · OMXSTO:MODTX
Modus Therapeutics Holding Ab — Q1 2025 Earnings Presentation
23 slides from Modus Therapeutics Holding Ab's earnings presentation, May 14, 2025
Slide 1: Modus Therapeutics Interim Report Q1 2025
MODUS THERAPEUTICS INTERIM REPORT Q1 2025 1
Slide 2: The First Quarter in Brief
JANUARY 1 – MARCH 31 2O25 THE FIRST QUARTER IN BRIEF The first quarter in figures Important events after the end of the period Financial overview • T he loss after tax amounted to TSEK 2 815 • Modus Therapeutics to present preclinical (3 105) data supporting sevuparin’s effects in 2025 2024 2024 chr
Slide 3: CEO Statement: Continued Clinical Progress and Global Engagement in Focus for 2025
CEO STATEMENT CONTINUED CLINICAL PROGRESS AND GLOBAL ENGAGEMENT IN FOCUS FOR 2025 Modus Therapeutics enters 2025 with clear bridge financing from our largest shareholder, clinical momentum, strengthened global Karolinska Development. Their continued support engagement, and a continued focus on under
Slide 4: Modus Strengthens Partnerships at the Global Roundtable on Health Innovation
CEO STATEMENT Modus Strengthens Partnerships at the Global Roundtable on Health Innovation 600,000 lives annually, predominantly among Moving Forward in 2025 BioEurope Spring 2025 Conference In March, I had the privilege of representing young children in sub-Saharan Africa. This As we move further i
Slide 5: About Modus Therapeutics
STATEMENT OF OPERATIONS ABOUT MODUS THERAPEUTICS Modus is developing sevuparin for patients with severe diseases and high unmet medical needs Modus Therapeutics is a Swedish biotechnology company developing sevuparin, an innovative drug candidate with the potential to transform the treatment of dise
Slide 6: Sevuparin – A Drug Candidate with Broad Clinical Potential
STATEMENT OF OPERATIONS SEVUPARIN – A DRUG CANDIDATE WITH BROAD CLINICAL POTENTIAL Modus Therapeutics is developing innovative for higher dosing without increased bleeding tecting the endothelium and neutralizing harmful stands out as an innovative drug candidate treatments for patients suffering fr
Slide 7: Market Overview
STATEMENT OF OPERATIONS MARKET OVERVIEW With sevuparin, Modus is targeting three The market potential is substantial. Modus, Anemia/CKD challenging indications—each with significant together with external analytics firm XPLICO, has standalone potential. identified an addressable market for sevuparin
Slide 8: Statement of Operations: Malaria and Sepsis Markets
STATEMENT OF OPERATIONS adapted mosquito vectors, and climate-related incentives in high-income countries. In the U.S., million deaths globally in 2017—about 20% of all changes that increase the incidence and severity malaria is classified as a rare disease (fewer global deaths that year. In the U.S
Slide 9: Business Model & Collaborations
STATEMENT OF OPERATIONS BUSINESS MODEL & COLLABORATIONS Business model operational and strategic capabilities. According to In non-endemic markets such as the US and EU, Given that sevuparin has the potential to be the first the current development plan, a market launch and malaria/severe malaria ma
Slide 10: Development of Profit and Financial Position
FINANCIAL REPORT DEVELOPMENT OF PROFIT AND FINANCIAL POSITION First quarter Operating profit/loss The operating loss for the period January – March 2025 amounted to 2 715 (3 199) TSEK. Research and development expenses decreased by 274 TSEK compared to the same period last year, mainly due to phasin
Slide 11: Important Events During the Quarter
FINANCIAL REPORT Important events during the quarter By targeting key mechanisms in the disease’s BioIron Society Congress, held on May 25–29 in Rossi, was opened in Verona at the study’s initiation pathophysiology, sevuparin has the potential to Montréal, Canada. The oral presentation, titled in De
Slide 12: Other Disclosures
FINANCIAL REPORT OTHER DISCLOSURES Ownership structure Financing favorable terms, or that such capital can be Risks and uncertainties At the end of the first quarter 2025, there were The Board of Directors regularly reviews the raised at all. The Board of Directors and the CEO Modus Therapeutics ris
Slide 13: Consolidated Summary Income Statement
FINANCIAL REPORT Consolidated summary income statement 2025 2024 2024 TSEK Jan 1 – Mar 31 Jan 1 – Mar 31 Jan 1 – Dec 31 Net sales - - - Research and development costs -1 211 -1 485 -9 067 Administration costs -1 514 -1 702 -6 727 Other operating income 10 -12 -44 Operating profit/loss -2 715 -3 199
Slide 14: Consolidated Summary Balance Sheet
FINANCIAL REPORT Consolidated summary balance sheet 2025 2024 2024 TSEK Mar 31 Mar 31 Dec 31 Assets Fixed Assets Other financial fixed assets 52 51 52 Total fixed assets 52 51 52 Current assets Other receivables 794 561 453 Cash equivalents 5 320 15 395 4 379 Total current assets 6 144 15 956 4 832
Slide 15: Consolidated Change in Shareholder's Equity in Summary
FINANCIAL REPORT Consolidated change in shareholder’s equity in summary 2025 2024 2024 TSEK Jan 1 – Mar 31 Jan 1 – Mar 31 Jan 1 – Dec 31 Opening balance equity 2 137 17 681 17 681 Profit/loss for the period -2 815 -3 105 -15 545 Total comprehensive income -2 815 -3 105 -15 545 New issue of shares -
Slide 16: Consolidated Cash Flow Statement in Summary
FINANCIAL REPORT Consolidated cash flow statement in summary 2025 2024 2024 TSEK Jan 1– Mar 31 Jan 1– Mar 31 Jan 1– Dec 31 Operating activities Operating profit/loss -2 715 -3 199 -15 838 Interest received - 94 292 Interest paid - - - Cash flow from operating activities before changes in working cap
Slide 17: Parent Company Income Statement in Summary
FINANCIAL REPORT Parent company income statement in summary 2025 2024 2024 TSEK Jan 1– Mar 31 Jan 1– Mar 31 Jan 1– Dec 31 Net sales 185 185 740 Research and development costs -358 -701 -1 450 Administration costs -1 372 -1 245 -6 110 Other operating expenses - - -1 Operating profit/loss -1 545 -1 76
Slide 18: Parent Company Balance Sheet
FINANCIAL REPORT Parent company balance sheet 2025 2024 2024 2025 2024 2024 TSEK Mar 31 Mar 31 Dec 31 TSEK Mar 31 Mar 31 Dec 31 Assets Current liabilities Non-current assets Interest-bearing liabilities 5 000 - - Financial assets 70 052 70 051 70 052 Accounts payable 567 322 144 Total non-current as
Slide 19: Notes
FINANCIAL REPORT NOTES Note 1. Accounting principles Note 4. Equity Modus Therapeutics Holding AB’s consolidated The share capital of the Parent Company accounts have been prepared in accordance consists only of fully paid ordinary shares with with the annual accounts act and the Swedish a nominal (
Slide 20: Signatures
FINANCIAL REPORT SIGNATURES The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the group and the parent company, and that it also describes the principal risks and uncertainties faced by the parent
Slide 21: Quarterly Overview
FINANCIAL REPORT QUARTERLY OVERVIEW 2025 2024 2025 The Group Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Definitions Financial key ratio Net sales, TSEK - - - - - - - - Operating profit Operating profit, TSEK -2 715 -4 846 -2 989 -4 804 -3 199 -3 771 -2 456 4 365 Operating income less operating expenses. Equity/Asset r
Slide 22: Leadership Team & Board
LEADERSHIP TEAM & BOARD John Öhd, M.D., PhD Claes Lindblad Viktor Drvota, M.D, PhD Johan Dighed Ellen K. Donnelly, PhD CEO since 2020 and previously CMO since CFO since 2021. Chairman since 2016. Board Member since September 2024. Board Member since 2020. 2018. Born: 1967 Born: 1965 Born: 1973 Born:
Slide 23: Contact
Olof Palmes gata 29 IV, 111 22 Stockholm, Sweden +46 (0)8-501 370 00 info@modustx.com www.modustx.com Contact John Öhd, CEO +46 (0)70-744 80 97 john.ohd@modustx.com Claes Lindblad, CFO & Head of IR +46 (0)70-246 75 54 claes.lindblad@modustx.com 23
Modus Therapeutics Holding — Q1 2025 Earnings Presentation on 6ix